EP2680879A4 - Peptide linkers for polypeptide compositions and methods for using same - Google Patents
Peptide linkers for polypeptide compositions and methods for using sameInfo
- Publication number
- EP2680879A4 EP2680879A4 EP12754246.2A EP12754246A EP2680879A4 EP 2680879 A4 EP2680879 A4 EP 2680879A4 EP 12754246 A EP12754246 A EP 12754246A EP 2680879 A4 EP2680879 A4 EP 2680879A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- methods
- same
- peptide linkers
- polypeptide compositions
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title 2
- 239000000203 mixture Substances 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/0105—Alpha-N-acetylglucosaminidase (3.2.1.50)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161449225P | 2011-03-04 | 2011-03-04 | |
PCT/US2011/041928 WO2011163652A2 (en) | 2010-06-25 | 2011-06-25 | Treatment of sanfilippo syndrome type b |
US13/168,969 US20110318327A1 (en) | 2010-06-25 | 2011-06-25 | Treatment of sanfilippo syndrome type b |
PCT/US2012/027561 WO2012122042A2 (en) | 2011-03-04 | 2012-03-02 | Peptide linkers for polypeptide compositions and methods for using same |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2680879A2 EP2680879A2 (en) | 2014-01-08 |
EP2680879A4 true EP2680879A4 (en) | 2015-09-02 |
EP2680879B1 EP2680879B1 (en) | 2021-01-06 |
Family
ID=49165891
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP12754246.2A Active EP2680879B1 (en) | 2011-03-04 | 2012-03-02 | Peptide linkers for polypeptide compositions and methods for using same |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP2680879B1 (en) |
JP (3) | JP6175372B2 (en) |
CN (2) | CN106279433A (en) |
AU (3) | AU2012225766B9 (en) |
BR (1) | BR112013022557A2 (en) |
CA (2) | CA2828966C (en) |
WO (1) | WO2012122042A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8580922B2 (en) | 2011-03-04 | 2013-11-12 | Shire Human Genetic Therapies, Inc. | Peptide linkers for polypeptide compositions and methods for using same |
HUE043679T2 (en) | 2012-11-27 | 2019-09-30 | Biomarin Pharm Inc | Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof |
US10603364B2 (en) | 2014-08-11 | 2020-03-31 | Shire Human Genetic Therapies, Inc. | Lysosomal targeting and uses thereof |
MA41022A (en) | 2014-11-24 | 2017-10-03 | Shire Human Genetic Therapies | LYSOSOMIAL TARGETING AND CORRESPONDING USES |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001005824A2 (en) * | 1999-07-15 | 2001-01-25 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Synthetic peptides immunoreactive with hepatitis a virus antibodies |
WO2011163652A2 (en) * | 2010-06-25 | 2011-12-29 | Shire Human Genetic Therapies, Inc. | Treatment of sanfilippo syndrome type b |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2222055A1 (en) * | 1995-05-23 | 1996-11-28 | Morphosys Gesellschaft Fur Proteinoptimierung Mbh | Multimeric proteins |
US20040181830A1 (en) * | 2001-05-07 | 2004-09-16 | Kovalic David K. | Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement |
US7629309B2 (en) * | 2002-05-29 | 2009-12-08 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
US20060099218A1 (en) * | 2002-10-01 | 2006-05-11 | Dnavec Research | Method of strengthening foreign epitope presentation by mhc class i by inhibiting tap activity |
JP4493327B2 (en) * | 2003-12-09 | 2010-06-30 | 三洋化成工業株式会社 | Cell adhesion polypeptide |
JP4897792B2 (en) * | 2005-04-20 | 2012-03-14 | ビロメッド カンパニー, リミテッド | Compositions and methods for separation of fusion proteins |
GB0511124D0 (en) * | 2005-06-01 | 2005-07-06 | Avidex Ltd | High affinity melan-a t cell receptors |
US7855279B2 (en) * | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
GB0524987D0 (en) * | 2005-12-08 | 2006-01-18 | Ge Healthcare Ltd | Novel imaging agents for fibrosis |
GB0611463D0 (en) * | 2006-06-09 | 2006-07-19 | Novartis Ag | Organic compounds |
US20090304719A1 (en) * | 2007-08-22 | 2009-12-10 | Patrick Daugherty | Activatable binding polypeptides and methods of identification and use thereof |
US8470771B2 (en) * | 2007-11-14 | 2013-06-25 | Institute Of Microbiology, Chinese Academy Of Sciences | Method and medicament for inhibiting the infection of influenza virus |
CN101186637B (en) * | 2007-11-14 | 2011-09-14 | 中国科学院微生物研究所 | Method for inhibiting influenza virus infection and medicament thereof |
ES2629853T3 (en) * | 2008-05-07 | 2017-08-16 | Biomarin Pharmaceutical Inc. | Lysosomal direction peptides and uses thereof |
TWI496582B (en) * | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | Bispecific egfr/igfir binding molecules |
US8697654B2 (en) * | 2008-12-18 | 2014-04-15 | E I Du Pont De Nemours And Company | Peptide linkers for effective multivalent peptide binding |
JP2012516452A (en) * | 2009-01-30 | 2012-07-19 | エイディーライフ インコーポレイティッド | Conformationally dynamic peptides |
-
2012
- 2012-03-02 EP EP12754246.2A patent/EP2680879B1/en active Active
- 2012-03-02 WO PCT/US2012/027561 patent/WO2012122042A2/en unknown
- 2012-03-02 CA CA2828966A patent/CA2828966C/en active Active
- 2012-03-02 CN CN201610670405.5A patent/CN106279433A/en active Pending
- 2012-03-02 CN CN201280020811.7A patent/CN103764162B/en active Active
- 2012-03-02 CA CA3080181A patent/CA3080181A1/en not_active Abandoned
- 2012-03-02 BR BR112013022557A patent/BR112013022557A2/en not_active Application Discontinuation
- 2012-03-02 AU AU2012225766A patent/AU2012225766B9/en active Active
- 2012-03-02 JP JP2013556654A patent/JP6175372B2/en active Active
-
2016
- 2016-08-03 JP JP2016152698A patent/JP6594833B2/en active Active
-
2017
- 2017-06-28 AU AU2017204405A patent/AU2017204405B2/en active Active
-
2019
- 2019-04-24 AU AU2019202865A patent/AU2019202865B2/en not_active Expired - Fee Related
- 2019-06-17 JP JP2019111936A patent/JP2019150065A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001005824A2 (en) * | 1999-07-15 | 2001-01-25 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Synthetic peptides immunoreactive with hepatitis a virus antibodies |
WO2011163652A2 (en) * | 2010-06-25 | 2011-12-29 | Shire Human Genetic Therapies, Inc. | Treatment of sanfilippo syndrome type b |
Non-Patent Citations (6)
Title |
---|
CAROLYN S. SINOW: "Construction of an IGF-NAGLU Fusion Protein for Treatment of Sanfilippo B Syndrome", 2008, XP002735889, Retrieved from the Internet <URL:https://www.usc.edu/CSSF/History/2008/Projects/S0417.pdf> [retrieved on 20150212] * |
GEORGE R A ET AL: "An analysis of protein domain linkers: their classification and role in protein folding", PROTEIN ENGINEERING, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 15, no. 11, 1 November 2002 (2002-11-01), pages 871 - 879, XP002374925, ISSN: 0269-2139, DOI: 10.1093/PROTEIN/15.11.871 * |
LEBOWITZ J H ET AL: "Glycosylation-independent targeting enhances enzyme delivery to lysosomes and decreases storage in mucopolysaccharidosis type VII mice", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 101, no. 9, 2 March 2004 (2004-03-02), pages 3083 - 3088, XP002285806, ISSN: 0027-8424, DOI: 10.1073/PNAS.0308728100 * |
ROBINSON C R ET AL: "Optimizing the stability of single-chain proteins by linker length and composition mutagenesis", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 95, no. 11, 26 May 1998 (1998-05-26), pages 5929 - 5934, XP002333428, ISSN: 0027-8424, DOI: 10.1073/PNAS.95.11.5929 * |
See also references of WO2012122042A2 * |
VISHNU PRIYANKA REDDY CHICHILI ET AL: "Linkers in the structural biology of protein-protein interactions", PROTEIN SCIENCE, vol. 22, no. 2, 8 February 2013 (2013-02-08), pages 153 - 167, XP055169244, ISSN: 0961-8368, DOI: 10.1002/pro.2206 * |
Also Published As
Publication number | Publication date |
---|---|
EP2680879B1 (en) | 2021-01-06 |
AU2012225766A1 (en) | 2013-09-19 |
AU2017204405A1 (en) | 2017-07-20 |
BR112013022557A2 (en) | 2017-08-01 |
AU2019202865A1 (en) | 2019-05-16 |
JP2019150065A (en) | 2019-09-12 |
CA2828966C (en) | 2020-07-14 |
JP6175372B2 (en) | 2017-08-02 |
JP2016187358A (en) | 2016-11-04 |
JP6594833B2 (en) | 2019-10-23 |
CN103764162B (en) | 2017-03-08 |
AU2012225766B9 (en) | 2017-08-31 |
CN106279433A (en) | 2017-01-04 |
CA3080181A1 (en) | 2012-09-13 |
CA2828966A1 (en) | 2012-09-13 |
AU2017204405B2 (en) | 2019-05-09 |
JP2014515595A (en) | 2014-07-03 |
WO2012122042A2 (en) | 2012-09-13 |
EP2680879A2 (en) | 2014-01-08 |
AU2012225766B2 (en) | 2017-07-13 |
WO2012122042A3 (en) | 2014-03-13 |
CN103764162A (en) | 2014-04-30 |
AU2019202865B2 (en) | 2021-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1249406A1 (en) | Aromatic-cationic peptides and methods for using same | |
HK1215934A1 (en) | Peptide therapeutics and methods for using same | |
IL230918A0 (en) | Modified proteins and peptides | |
ZA201206832B (en) | Novel peptides and method for their preparation and use | |
EP2728002A4 (en) | Heterodimerized polypeptide | |
EP2771033A4 (en) | Protein formulations containing amino acids | |
IL233280B (en) | Cell-penetrating peptides | |
EP2738255A4 (en) | Erap1-derived peptide and use thereof | |
GB201012651D0 (en) | Peptides | |
ZA201302113B (en) | Caspofungin composition | |
ZA201305591B (en) | Fluorocarbon-linked peptide formulation | |
PL2768848T3 (en) | Agents and methods for the expression and secretion of peptides and proteins | |
EP2793921A4 (en) | Saposin-a derived peptides and uses thereof | |
GB201111183D0 (en) | Peptide | |
EP2576593A4 (en) | Methods for the synthesis of dicarba bridges in peptides | |
EP2742153A4 (en) | Protein and peptide libraries | |
EP2747773A4 (en) | Methods and compositions comprising a c-terminal bax peptide | |
GB201016494D0 (en) | Polypeptide | |
EP2680879A4 (en) | Peptide linkers for polypeptide compositions and methods for using same | |
EP2627674A4 (en) | Egfr-based peptides | |
EP2762149A4 (en) | Erythropoietin-derived peptide and use therefor | |
EP2793918A4 (en) | Hdc-sign binding peptides | |
HK1187628A1 (en) | Novel peptide | |
EP2771689A4 (en) | Usp2a peptides and antibodies | |
HK1203150A1 (en) | Improved processes for preparing peptide conjugates and linkers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20130903 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
R17D | Deferred search report published (corrected) |
Effective date: 20140313 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1193352 Country of ref document: HK |
|
DAX | Request for extension of the european patent (deleted) | ||
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12N 9/24 20060101ALI20150303BHEP Ipc: A61P 43/00 20060101ALI20150303BHEP Ipc: A61K 38/47 20060101AFI20150303BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20150731 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 47/48 20060101ALI20150727BHEP Ipc: A61K 38/47 20060101AFI20150727BHEP Ipc: C07K 7/08 20060101ALI20150727BHEP Ipc: C12N 9/24 20060101ALI20150727BHEP Ipc: A61P 43/00 20060101ALI20150727BHEP Ipc: C07K 14/65 20060101ALI20150727BHEP Ipc: A61K 38/46 20060101ALI20150727BHEP Ipc: A61K 38/30 20060101ALI20150727BHEP Ipc: A61K 9/00 20060101ALI20150727BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20170228 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 14/65 20060101ALI20200622BHEP Ipc: A61K 38/30 20060101ALI20200622BHEP Ipc: A61K 9/00 20060101ALI20200622BHEP Ipc: A61K 38/46 20060101ALI20200622BHEP Ipc: C12N 9/24 20060101ALI20200622BHEP Ipc: A61K 38/47 20060101AFI20200622BHEP Ipc: A61K 47/65 20170101ALI20200622BHEP Ipc: A61P 43/00 20060101ALI20200622BHEP Ipc: C07K 7/08 20060101ALI20200622BHEP |
|
INTG | Intention to grant announced |
Effective date: 20200722 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1351625 Country of ref document: AT Kind code of ref document: T Effective date: 20210115 Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602012074026 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20210106 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1351625 Country of ref document: AT Kind code of ref document: T Effective date: 20210106 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210106 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210506 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210106 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210106 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210407 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210406 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210406 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210106 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210106 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210106 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210106 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210106 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210106 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210506 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602012074026 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210106 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210106 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210106 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210106 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210106 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210106 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210106 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210106 |
|
26N | No opposition filed |
Effective date: 20211007 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20210331 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20210406 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210331 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210106 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210331 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210302 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211001 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210306 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210302 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210406 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210106 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210106 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210506 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210331 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20120302 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210106 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210106 |